| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00000542-199802000-00006 |
| P8608 | Fatcat ID | release_vizvsemzazeejl2lsp6xb272ru |
| P698 | PubMed publication ID | 9477048 |
| P2093 | author name string | Gay M | |
| Pace NL | |||
| Busch MA | |||
| Streisand JB | |||
| Smith BG | |||
| Egan TD | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| fentanyl | Q407541 | ||
| P304 | page(s) | 305-309 | |
| P577 | publication date | 1998-02-01 | |
| P1433 | published in | Anesthesiology | Q2012635 |
| P1476 | title | Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. | |
| P478 | volume | 88 |
| Q44073685 | A comparison of oral transmucosal fentanyl and oral midazolam for premedication in children |
| Q26862553 | A comprehensive review of rapid-onset opioids for breakthrough pain |
| Q44541854 | A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate |
| Q48618437 | Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate |
| Q37095373 | Advanced formulation design: improving drug therapies for the management of severe and chronic pain |
| Q43647253 | Caregiver toxicity from transdermal fentanyl |
| Q38090468 | Considerations in selecting rapid-onset opioids for the management of breakthrough pain |
| Q42459158 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial |
| Q47792205 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain |
| Q36219854 | Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines |
| Q45019837 | Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects |
| Q37907299 | Fentanyl for breakthrough pain: a systematic review |
| Q39293912 | Formulations of fentanyl for the management of pain |
| Q44638919 | In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance |
| Q38205892 | Management of the acute painful crisis in sickle cell disease- a re-evaluation of the use of opioids in adult patients |
| Q37912136 | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients |
| Q34749086 | Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications |
| Q43706125 | Oral transmucosal fentanyl and sufentanil for incident pain |
| Q36135142 | Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics |
| Q46978958 | Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS) |
| Q39376692 | Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series |
| Q36920427 | Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology |
| Q36502945 | Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics |
| Q36290097 | Oral transmucosal fentanyl pretreatment for outpatient general anesthesia |
| Q37994343 | Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients |
| Q37419356 | Pediatric palliative care: use of opioids for the management of pain |
| Q35826726 | Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain |
| Q48298084 | Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects |
| Q60673767 | Pharmacology of opioid analgesia: clinical principles |
| Q35095194 | Pharmacotherapy of cancer-related episodic pain |
| Q53681112 | Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. |
| Q34655361 | Recent advances in pharmacotherapy for cancer pain management |
| Q34418203 | Recent advances in the use of opioids for cancer pain |
| Q39365689 | Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study |
| Q44669972 | Self-treatment with oral transmucosal fentanyl citrate to prevent emergency room visits for pain crises: patient self-reports of efficacy and utility |
| Q44884225 | Simultaneous extraction and quantitation of fentanyl and norfentanyl from primate plasma with LC/MS detection |
| Q34297489 | Strategies for the treatment of cancer pain in the new millennium |
| Q80762595 | [Cancer pain management. Basic therapy and treatment of breakthrough pain] |
Search more.